2016-02-24 20:18:04 UTC
Feb. 25, 2016
83.5 percent of the frozen FMT group and 85.1 percent of the fresh FMT group achieved clinical resolution in this Canadian study, recently published in JAMA.
Using frozen stool material in fecal microbiota transplantation (FMT) may help ease some of the difficulties involved in the FMT process without sacrificing efficacy.
According to a newly published study in the Journal of American Medicine, which was highlighted in GI & Hepatology News, “FMT using frozen-then-thawed fecal material proved noninferior to that using fresh material for treating recurrent or refractory Clostridium difficile infection.” Specifically, 83.5 percent of the frozen FMT group and 85.1 percent of the fresh FMT group achieved clinical resolution.
The study, led by Christine H. Lee, MD, of the department of pathology and molecular medicine at McMaster University in Canada, looked at patients over the course of two years. Lee and her team compared frozen with fresh donor material in 232 adults with recurrent or refractory C. difficile infection, many of whom had IBD and were immunocompromised.
Lee said that in addition to lessening some of the logistical issues involved with fresh FMT, using frozen FMT could increase the accessibility to the treatment, and also reduce the number and frequency of donor screenings, thus reducing costs.
For more information on FMT, read this GI & Hepatology News article or visit the AGA Center for Gut Microbiome Research and Education.